Fungal keratitis in Scandinavia, a temperate climate
June 13 2014
Over 14 years, 25 cases of confirmed fungal keratitis were treated in 2 centres in Denmark—a population rate of >0.6/1,000,000 per year. Over half the cases were caused by Candida spp., which had a worse outcome. This frequency contrasts with subtropical and tropical areas in which Aspergillus and Fusarium species are more common.
Increasing incidence of invasive fungal infections in France
June 10 2014
A new population-based analysis by Bitar et al. at the Institute of Health Surveillance, Paris, reveals an increasing incidence of invasive fungal infections (IFIs) in France. A national hospital database covering >95% of France’s hospitals was utilised in an epidemiological study, identifying hospital stays between 2001-2010 for which IFIs were the primary cause of admission. 35,876 cases were identified, excluding patients staying in the hospital more than once and inconsistently-recorded cases.
Itraconazole versus trimethoprim-sulfamethoxazole (TMP-SMX) in paracoccidioidomycosis
May 27 2014
Paraoccidioidomycosis (PCM) is a systemic fungal infection native to subtropical areas of Latin America. It causes over 3000 new cases annually; of these patients, around 5% will die of the infection. Various therapeutic options have been used to successfully treat PCM including sulfonamide derivatives (e.g. trimethoprim-sulfamethoxazole; TMP-SMX) and azole antifungals (such as itraconazole). Previous literature and current Brazilian Consensus guidelines for PCM suggest that itraconazole may be more effective than TMP-SMX; however, there are few reports in the literature comparing efficacy of these two regimens.
Limited availability of generic antifungals across the world
May 15 2014
In a global analysis, GAFFI has identified major gaps in antifungal drug provision for common fungal infections. From multiple sources—most directly from individual countries—it shows flucytosine availability in 24%, amphotericin B deoxycholate in 49%, itraconazole in 93% and fluconazole in 98% of countries (including PEPFAR provision). No antifungals are available in Afghanistan.
Burden of serious fungal diseases presented at ECCMID for Czech Republic, Denmark, Germany, Hungary,
May 11 2014
The burden serious fungal disease from 6 European countries, Vietnam and Iraq, covering a total of 340 million people, has been presented at the ECCMID conference in Barcelona on May 10-13th 2014. The estimate from Vietnam is the first SE Asian country to be modelled. Notably different from other countries include high rates of Candida bloodstream infections in Denmark (8/100,000), increasing Pneumocystis pneumonia rates in the UK and Germany (0.94 and 1.2/100,000) and high rates of both chronic pulmonary aspergillosis (61/100,000) and tinea capitis (457/100,000) in Vietnam. Ukraine appears to have generally very high frequencies of several key infections.